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The immune system is functionally diverse, able to make 
a  refined  response  to  hundreds  of  different  types  of 
infectious  organisms.  The  initiation  of  an  immune 
response to an infection requires collaboration between 
innate  immune  cells,  which  recognize  general  distin­
guishing features of pathogens, and the T lymphocytes of 
the  adaptive  immune  system,  whose  highly  variable 
antigen receptors are specific for a given pathogen. The 
activation  of  T  lymphocytes  depends  on  interactions 
with  professional  antigen­presenting  cells  (APCs), 
specialized cells of the innate immune system that are 
directly  activated  by  the  pathogens  they  engulf  and 
regurgitate for presentation to, and activation of, T cells. 
The T cells then proliferate and are mobilized to protect 
the body by activating other immune cells or by killing 
infected cells. Among the immune cells activated by T 
lymphocytes, most importantly, are the B lymphocytes 
that produce antibodies. T lymphocytes direct the types 
of antibodies that B cells produce and the activity of other 
immune cells, thereby directing the immune response to 
optimally  provide  protection  against  different  types  of 
infections.
At  the  end  of  an  immune  response,  the  majority  of 
activated B and T cells will undergo apoptosis, but a small 
number remain as memory cells, primed ready in case 
the host is exposed to the same infection [1,2]. Vaccines 
must  work  in  a  similar  way,  priming  antigen­specific 
T and B cells, some of which convert to the memory cells 
that  will  control  subsequent  infections  by  the  invader 
targeted by the vaccine. Moreover, like the infection itself, 
the  vaccine  must  generate  the  optimal  type  of  immune 
response to protect against a particular pathogen.
The different ways in which the immune system can 
respond  to  antigen  are  schematically  summarized  in 
Figure  1,  which  shows  the  two  major  classes  of 
T  lymphocyte,  cytotoxic  (or  CD8)  cells  and  helper  (or 
CD4) cells, and their principal actions. For example, virus 
infections can be cleared by cytotoxic T cells (CTLs) or 
antibodies,  whereas  intracellular  bacteria  and  parasites 
are most effectively controlled by T cells that produce 
cytokines  specialized  to  activate  particular  groups  of 
innate immune cells (Figure 1) [3­5].
The  immune  system  is  thought  to  distinguish  the 
different  kinds  of  pathogens  through  recognition  by 
innate  immune  cells  of  pathogen­associated  molecular 
patterns  (PAMPs)  on  microorganisms,  which  enables 
responding cells to direct the adaptive responses along 
the  pathway  that  will  best  help  to  reject  the  invader. 
PAMPs  include,  for  example,  characteristic  cell  wall 
components of bacteria, double­stranded RNA, which is 
found in some viruses, and CpG­rich DNA, which can be 
present in bacteria and viruses. These microbial compo­
nents are detected by innate signaling pattern recognition 
receptors  (PRRs),  among  the  best  known  and  most 
versatile  of  which  are  the  Toll­like  receptors  (TLRs). 
Different  members  of  the  TLR  family  of  membrane­
bound receptors are specialized for detection of different 
classes  of  pathogens.  In  addition,  many  cytoplasmic 
proteins have recently been recognized to be important 
in innate immunity as PRRs [6­9]. Recognition of PAMPs 
by  responding  cells  promotes  recruitment  of  innate 
immune cells and APCs and activates APCs, increasing 
uptake  of  antigen  and  inducing  cell­surface  molecules 
and  soluble  mediators  that  are  required  for  T  cell 
activation.  Together,  these  effects  influence  the 
magnitude of T and B cell responses and the numbers of 
memory cells that are produced. Not only do they serve 
to warn and activate the cells of the adaptive immune 
response but, impor  tantly, they also control the type of 
immune response that follows.
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Hope of Progress
© 2010 McKee et al.; licensee BioMed Central Ltd.Currently,  three  main  types  of  vaccine  are  used  in 
humans: live attenuated vaccines composed of a virus or 
bacterium that is similar to but less pathogenic than the 
real  pathogen;  inactivated  vaccines  that  are  heat­
inactivated  or  chemically  inactivated  particles  of  the 
pathogen;  or  subunit  vaccines  that  are  made  from 
components of the pathogen. Vaccines contain not only 
the  antigen  that  is  the  target  of  the  adaptive  immune 
response,  but  either  PAMPs  or  other  substances  that 
amplify  or  influence  the  adaptive  response:  these  are 
known as adjuvants. In the live attenuated vaccines, the 
antigens that are recognized by the cells of the adaptive 
immune system are coupled to the PAMPs that activate 
professional APCs, just as they are in the pathogen itself, 
and  these  thus  provide  a  natural  adjuvant.  Subunit 
vaccines, by contrast, consist of the purified antigens that 
are specifically recognized by lymphocytes, and although 
they  are  safer  than  whole­organism  vaccines,  they  are 
unable,  on  their  own,  to  activate  the  immune  system 
optimally  because  they  lack  intrinsic  PAMPs.  Such 
vaccines require the addition of adjuvants that enhance 
their immunogenicity and influence the magnitude and 
nature of the response.
Adjuvants  may  promote  immune  responses  by 
recruiting professional APCs to the vaccination site, by 
increasing  the  delivery  of  antigens  to  APCs,  or  by 
activating  APCs  to  produce  cytokines  and  provide 
activating signals to T cells. One adjuvant that has a long 
historical  use  in  human  vaccines  is  aluminum  salt 
(sometimes  referred  to  as  alum).  Proteins  from  the 
pathogen are adsorbed onto the aluminum salt, creating 
a suspension that is injected intramuscularly. Despite its 
long­standing and widespread use in human vaccines, it 
is  still  not  clear  exactly  how  this  adjuvant  works. 
Although it was widely believed that aluminum adjuvants 
promote  their  effects  by  maintaining  a  slow­releasing 
depot of antigen to the immune system, it is now clear 
that they promote multiple effects on the innate immune 
system.  In  addition,  excision  of  aluminum  adjuvant 
nodules  after  immunization  has  no  impact  on  the 
magnitude of the immune response, which has brought 
the role of the depot into question [10].
Adjuvants  were  first  deliberately  introduced  into 
vaccines  after  it  was  shown  that  aluminum  salts  and 
other particles could enhance immune responses [11]. At 
present, there are very few licensed vaccine adjuvants for 
clinical use. In the USA, aluminum salts have been, for 
many years, the only adjuvants that could be added to 
human  vaccines.  Recently,  monophosphoryl  lipid  A 
(MPL), a derivative of the highly immunogenic bacterial 
cell wall component lipopolysaccharide (LPS), has been 
approved  for  use  in  the  GlaxoSmithKline  vaccine  for 
Figure 1. Activation and differentiation of T lymphocytes. Dendritic cells (DCs) take up antigen delivered either by an infectious pathogen or 
by a vaccine (stage 1). DCs are activated by conserved components of pathogens binding to pattern recognition receptors (PRRs) that induce the 
expression of co-stimulatory molecules and the release of inflammatory cytokines. Vaccines that do not contain intrinsic adjuvants are delivered 
with added adjuvants, such as aluminum salts, that also activate inflammatory pathways. DCs degrade the antigen into peptides that are returned 
to the cell surface on MHC molecules and presented to CD8 and CD4+ T cells - antigen being presented to CD8+ T cells by MHC class I molecules, 
and to CD4+ T cells on MHC class II molecules (stage 2). T cells also require signals provided by the co-stimulatory molecules and inflammatory 
cytokines to be fully activated. Activation results in cell proliferation (stage 3) and effector cell differentiation (stage 4). CD4+ T cells can make 
cytokines that activate innate immune cells (such as macrophages and neutrophils) to kill pathogens. Activated CD4+ T cells can also provide help 
to B cells, expressing the cell-surface and soluble mediators required for the production of high-affinity class switched antibody. Effector CD8+ T 
cells can kill infected cells by releasing cytotoxic granules or can activate other cell types by the release of inflammatory cytokines.
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Page 2 of 10human  papillomavirus  in  combination  with  aluminum 
hydroxide.  In  Europe  several  additional  adjuvants  are 
used,  including  the  oil­in­water  adjuvants  MF59  and 
ASO3,  made  by  Novartis  and  GlaxoSmithKline, 
respectively (Table 1). As well as these, a large number of 
novel  vaccine  adjuvants  have  been  studied  in  the 
laboratory,  and  some  of  them  have  also  been  used  in 
clinical trials in humans (Tables 1 and 2). Whether these 
adjuvants will pass the two major criteria required for 
general  use  (effectiveness  and  safety)  remains  to  be 
determined.
Adjuvants and antibody production
Most current vaccines act by inducing long­lived plasma 
cells ­ terminally differentiated B cells ­ that continuously 
secrete antibody over a considerable period of time [5]. 
Antibodies act quickly by binding to and thus stopping 
the pathogen, or products of the pathogen, in their tracks 
before damage to the host occurs. They are thus ideal for 
control of many diseases, including infection by viruses 
and  intoxication  by  a  number  of  bacterial  products, 
including tetanus and diphtheria toxins [5]. Many of the 
viral  vaccines  use  attenuated  viruses  as  agents  and 
generate  good,  long­lasting  antibody  production  [12]. 
However, this is not so true for the subunit vaccines. For 
example,  the  tetanus  vaccine,  which  is  composed  of  a 
toxoid  (an  inactivated  toxin  that  retains  its  antigenic 
properties) adsorbed to aluminum adjuvant, leads to the 
generation of plasma cells that make anti­tetanus­toxin 
antibody.  However,  this  vaccine  is  routinely  given  to 
individuals every 10 to 15 years as the specific plasma 
cells making the antibody eventually die off [13]. This is 
in  contrast  to  the  plasma  cells  that  are  generated 
following infection with live measles virus. These plasma 
cells are predicted to have a half­life of 3,014 years [12]. 
How the infection manages this and, therefore, how an 
adjuvant could achieve this are still unclear.
Table 1. Adjuvants in use or being tested for use in human vaccines
Adjuvant  Composition  Current status  References
Aluminum   Aluminum hydroxide or aluminum phosphate  In use in vaccines against DT, DPT, HBV, Hib, Streptococcus pneumoniae,   [94]
salts (alum)  non-crystalline gels  meningococcal and HPV infections
MF59  Oil (squalene)-in-water emulsion  In use in influenza vaccine (Europe); in trials for malarial, hepatitis C   [18,95-99] 
    and HIV vaccine systems
MPL  Non-toxic derivative of LPS   Used in various trials in combination with oil (squalene)-in-water   [87,100] 
    emulsions for malaria and leishmaniasis or in liposomal formulation
QS21  Purified fraction of Quil A   Trialed alone and in combination with MPL (AS02, AS01) for malaria,   [87] 
    influenza and cancers
ISCOMS  Liposomes containing QS21  Trials for influenza vaccines  [101,102]
AS01  Liposomal formulation containing MPL and QS21  Trials for malaria vaccines (a more effective formulation than AS03 and AS04)   [87]
AS02  Oil (squalene)-in-water emulsion of MPL and QS21  Trials for malaria, HBV and TB vaccines  [103]
AS03  Oil (squalene)-in-water emulsion  Trials for influenza vaccines  [20,21]
AS04  Aluminum hydroxide and MPL  Trials for HBV and HPV vaccines  [104,105]
MPL-SE  MPL in a oil (squalene)-in-water emulsion  Trials for leishmaniasis vaccines  [100]
Abbreviations: DPT, Diphtheria pertussis tetanus toxoid; DT, Diphtheria toxoid; HBV, Hepatitis B virus; Hib, Haemophilus influenzae , HIV, human immunodeficiency virus; 
HPV, human papilloma virus; ISCOMs, immune stimulating complexes; LPS, lipopolysaccharide; MPL, monophosphoryl lipid A; TB, tuberculosis.
Table 2. Proposed mechanisms of adjuvant activity of major adjuvant components
Adjuvant  Composition  Adjuvant activity  Mechanism of adjuvant action  References
Aluminum  AlOH or AlPO4 non-crystalline gels  Antibody and TH2 cells  ↑ Chemokine/cytokine production; ↑ recruitment of  [31,34, 46,
salts      monocytes and differentiation to DC; ↑ antigen uptake   106,107]
      by DC
MF59  Oil (squalene)-in-water emulsion  ↑ Ab titre; ↑ Ab cross-reactivity;   ↑ Chemokine/cytokine production; recruitment of  [34,
    drives TH2 cells  myeloid DCs to injection site; ↑ antigen uptake by DCs  108-110]
TLR ligands  MPL, GpG, imiquimod, resiquimod   Drives TH1 and CTL cells;   TLR signaling in DCs promotes antigen presentation  [111]
  (both imidazoquinolinamines) or   ↑ T cell memory  on MHC I and MHC II, enhanced migration of DCs to 
  poly(I:C)     lymph nodes and DCs cytokine production; may have  
      direct impacts on lymphocytes
QS21  Purified fraction of Quil A that   Antibody, TH1 and CTL  Enhances protective responses through poorly  [97]
  has lower toxicity and retains   responses  understood mechanisms; has lytic capacity and local   
  adjuvant effects     reactogenicity 
Abbreviations: Ab, antibody; CTL, cytotoxic T lymphocyte; MPL, monophosphoryl lipid A; poly(I:C), a synthetic analog of double-stranded RNA; Th, T helper cell; TLR, 
Toll-like receptor.
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adjuvant. There are five major classes of antibody with 
different  properties  and,  ideally,  vaccines  should  be 
designed to induce the antibody class that would be most 
effective in dealing with the pathogen. Immunoglobulin A 
(IgA) is highly effective against agents that infect through 
mucosal surfaces (see, for example, [14]). This factor may 
be responsible for the overall greater effectiveness of the 
Sabin (live attenuated) than the Salk (heat killed) polio 
vaccine. This is because the oral, live vaccine induces IgA 
secretion in the gut and respiratory tract, whereas the 
inactivated intramuscular Salk vaccine does not [15]. It is 
possible  that  adjuvants  can  be  selected  to  enhance 
secretory IgA production, probably through their effects 
on APCs and T cell differentiation (see below).
Antibodies are sometimes not enough
Influenza vaccines operate by inducing antibodies against 
the  two  main  surface  proteins  from  the  virus,  hemag­
glutinin and neuraminidase. In so doing they effectively 
protect against infection by influenza strains expressing 
versions  of  these  proteins  present  in  the  vaccine. 
However, these two proteins change as a consequence of 
mutation  and  re­assortment  and  the  vaccine  must  be 
reformulated each year to contain the hemagglutinin and 
neuraminidase  of  the  expected  strain.  Moreover,  the 
vaccine has historically been, and in the US is currently, 
administered in the absence of an adjuvant. This means 
that larger doses must be given and immunity has been 
difficult to induce against the proteins found in emerging 
strains, such as those in H5N1 viruses that cause avian flu 
[16]. This may be partly because individuals have memory 
cells that can recognize annual but not emerging strains 
of the virus. Memory cells can respond in the absence of 
high levels of co­stimulation [17] (Figure 1) and, there­
fore, can be activated in the absence of an adjuvant. A 
primary response is required, however, to protect against 
newly  emerging  virus  strains  as  they  are  more  anti­
genically  distinct  from  annual  influenza  strains.  This 
primary response cannot be activated in the absence of 
the inflammation induced by added adjuvant.
Addition of adjuvants (MF59, ASO3 or aluminum salts; 
Table 1) to influenza vaccines increases antibody titers 
and persistence [18­21]. However, these approaches do 
not  provide  cross­reactivity  to  distinct  subtypes  of  the 
virus.  The  same  is  true  for  the  attenuated  influenza 
vaccine  Flu­Mist,  which  is  also  modified  each  year, 
although this vaccine may activate cross­reactive CD8+ T 
cells, at least in children [22]. CD8+ T cells recognize less 
variable  parts  of  the  virus  ­  for  example,  in  the  core 
proteins [23­30] ­ and may provide a more cross­reactive 
response that could be induced by new vaccines.
Besides  influenza  there  are  clearly  many  other 
infections,  HIV  and  malaria,  for  example,  for  which 
antibodies are not at all, or are insufficiently, protective. 
In  these  cases,  both  humoral  immunity,  mediated  by 
antibodies, and cell­mediated immunity, which depends 
on cytotoxic T cells or T cells that activate immune cells 
by  means  of  cytokines,  may  be  required  for  effective 
protection.
Contribution of adjuvants to T cell priming
Dendritic cells (DCs) are key antigen­presenting cells in 
the initiation of T cell responses, and are thus likely to be 
a  major  target  of  adjuvant  effects.  In  the  absence  of 
infection, DCs are distributed throughout the tissues as 
phagocytic cells. The presence of infection is signaled to 
these cells both directly, by pattern­recognition receptors 
(PRRs)  for  microbial  constituents,  and  indirectly,  by 
inflammatory cytokines released by other innate immune 
cells that recognize microbial constituents. These signals 
activate the DCs to undergo a process known as matura­
tion  and  to  migrate  into  secondary  lymphoid  organs 
where they activate naïve T cells. DC maturation involves 
increased processing of microbial proteins, portions of 
which are presented to T cells on major histocompatibility 
complex (MHC) molecules (discussed below). This serves 
as a required first activation signal. In addition, activation 
of DCs by PRRs results in expression on the surface of 
the  DCs  of  so­called  accessory  and  co­stimulatory 
molecules and the secretion of cytokines. Co­stimulatory 
signals are secondary signals required for DCs to activate 
naïve T cells, and cytokines offer a third signal to direct 
their differentiation along different pathways (Figure 1, 
stage 2). One way in which adjuvants such as aluminum 
salts  and  MF59  act  is  by  promoting  inflammation  and 
infiltration  of  DCs  into  the  site  of  inoculation  and 
improving  the  uptake  of  associated  antigens  by  DCs 
[31­34].
Adjuvant effects are relatively well understood for signals 
that induce T helper cell 1 (TH1) responses, which are 
characterized by T helper cells that produce high levels of 
IFNγ,  and  other  cytokines  that  activate  antimicrobial 
effects at the effector site. These TH1 driving signals are 
known to operate through TLRs to induce secretion of 
interleukin  (IL)­12,  which  drives  differentiation  of  TH1 
cells [35­38]. Adjuvants such as QS21 or other saponins 
drive  TH1  responses  and  are  thought  to  work  by  the 
induction of IL­12 in DCs [39]. Aluminum salts, however, 
do not directly induce signaling through TLRs and do not 
stimulate IL­12 production by DCs. Instead, aluminum 
adjuvants drive TH2 responses [40], by mechanisms that 
are much less well understood.
The  requirements  for  antigen  presentation  to  CD8+ 
T  cells,  which  give  rise  to  cytotoxic  cells,  are  distinct 
from those for the CD4 helper T cells. CD8+ T cells are 
specialized for detection of agents, such as viruses, that 
invade the cytoplasm, and the pathway by which antigen 
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the pathway followed by internalized antigen. Briefly, all 
antigens  are  carried  to  the  cell  surface  by  molecules 
encoded in the MHC. Internalized antigen is carried to 
the cell surface by one class of MHC molecules, MHC 
class  II,  which  promotes  activation  of  CD4  cells.  In 
contrast, endogenous antigen reaches the cell surface on 
a different class, MHC class I, which activates CD8 cells. 
To activate cytotoxic T cells, antigen internalized by DCs 
must  cross  to  the  MHC  class  I  pathway  before 
reappearing on the cell surface, a process known as cross­
presentation,  for  which  specific  subsets  of  DCs  are 
specialized  [41].  Adjuvant  systems  are  likely  to  have 
important  effects  on  antigen  cross­presentation.  For 
example, some TLR ligands, such as LPS, can promote 
delivery of essential parts of the MHC class I antigen­
processing  pathway  to  vesicles  of  the  internalization 
pathway, presumably enhancing cross­presentation [42]. 
Other adjuvants, such as immunostimulatory complexes 
(ISCOM/ISCOMATRIX), particulate adjuvants made up 
of lipids, cholesterol and the saponin adjuvant Quil A, 
may promote cross­presentation and activation of CD8 
cells by partly bypassing the normal antigen­processing 
pathway [43].
The role of adjuvant­induced inflammation in enhanc­
ing  the  initiation  of  T  cell  responses  is  an  unresolved 
issue. For example, a crucial complex in the inflammatory 
pathway, the inflammasome, is suggested in some studies 
[44,45],  but  not  in  others  [46­48],  to  be  required  for 
recruitment  of  APCs  and  enhanced  T  and  B  cell 
responses  following  immunization  with  aluminum  salt 
adjuvants,  despite  the  use  of  similar  methods  in 
genetically  identical  mice.  It  is  also  not  clear  whether 
PRR­mediated  pathways  must  be  activated  in  DCs 
themselves, or whether inflammatory responses in local 
tissue cells can account for some adjuvant effects [49]. 
For example, inflammatory cytokines can recruit to the 
injection  site  monocytes  that  differentiate  into  DCs. 
These may subsequently be activated to migrate into the 
lymph  node  to  present  antigen  to  T  cells.  Such 
recruitment  is  one  action  of  the  MF59  adjuvant,  an 
emulsion of oil (squalene) in water, and aluminum salt 
adjuvants [31,34].
Establishment of T cell memory
Despite many years of research, immunologists still have 
little idea of which signals are required for the generation 
of memory T cells. This may be a stochastic process, in 
which  a  percentage  of  cells  are  randomly  selected  to 
survive, or a selective process, in which a subset of cells is 
designated early in the response to survive and generate 
the  memory  pool.  Memory  cells  can  be  identified  by 
characteristic  markers  [50­52]  that  may  be  useful  in 
measur  ing the effectiveness of different antigen­adjuvant 
combinations. In some cases, the generation of memory 
cells that express lymphoid homing markers is associated 
with  long­term  survival  and  thus  protection  [53].  In 
contrast, other investigators argue that memory T cells that 
migrate into non­lymphoid organs, where re­infec  tions are 
likely to occur, provide the most effective protection [54]. 
Therefore,  measurements  of  protective  capacity  (for 
example,  reduced  viral  titers  or  bacterial  loads  following 
challenge) are more useful indicators of a successful vaccine 
than the phenotype of the memory cells.
Many variables can affect the number and phenotype 
of memory cells. For example, a large dose of antigen can 
activate a larger number of cells, but a low dose may be 
preferable in a vaccine, if it activates only cells with high­
affinity receptors, which may be more effective in some 
infections [55,56]. This seems to be true in mouse models 
of Mycobacterium tuberculosis in which low­dose priming 
induces highly sensitive T cells that can make a broad 
cytokine response that is associated with protection [55].
Likewise,  the  amount  of  inflammation,  which  in  the 
case of a vaccine can be influenced by the addition of an 
adjuvant,  affects  the  phenotype  and  number  of  the 
memory  cells  generated,  partly  because  inflammatory 
signals  are  required  for  the  efficient  expansion  and 
survival of T cells [57]. The speed with which memory 
cells  are  generated,  however,  can  be  increased  by 
reducing inflammation during priming, resulting in the 
more rapid generation of memory cells [58,59]. It may be 
critical, therefore, to adjust the amount of antigen and 
adjuvant  depending  on  how  many  and  what  type  of 
memory  cells  are  required  to  provide  protection.  This 
leads us to the question of how important the two major 
classes  of  T  cells  ­  CD4  cells  and  CD8  cells  ­  are  in 
providing protection.
CD4 T cell-mediated protection
It is clear that CD4+ T cells are critical directors of both 
cellular and humoral memory. It has been established for 
many years that CD4+ T cells provide help to B cells [60], 
but CD4+ T cells are also crucial for the generation of 
effective CD8 memory T cells [61]. Any vaccine, regardless 
of its intended action, must therefore activate helper CD4+ 
T  cells.  Perhaps  the  most  important  considera  tion  for 
deciding what adjuvant to use in a vaccine is what type of 
CD4+ T cell response is required to direct the ensuing 
ideal  immune  response.  At  least  five  subsets  of  CD4+ 
T helper are now recognized: TH1 and TH2 cells, which 
activate  macrophages  in  distinct  ways  and  induce 
production  of  different  classes  of  antibodies  in  B  cells; 
TH17  cells,  which  are  inflammatory;  T  follicular  cells, 
which are specialized for activating B cells; and regulatory 
T  cells,  which  are  thought  to  prevent  autoimmunity 
(Figure 2). These subsets have been reviewed extensively 
elsewhere [62,63]; here we will mainly discuss TH1 cells as 
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vaccination.
Although it is clear that CD4+ T cells must be activated 
following vaccination, the importance of generating CD4 
memory cells is less obvious. We have recently discussed 
the subject in some detail [64] and so will not go into 
specifics  here,  but  a  careful  analysis  of  the  available 
evidence suggests that relatively few protective immune 
responses depend on CD4+ T cell memory. Protection 
from M. tuberculosis is, however, a good example of how 
CD4 memory cells can act. CD4+ T cells producing the 
important cytokine interferon (IFN)γ provide protection 
to M. tuberculosis by activating macrophages in infected 
lungs  [4].  The  current  M.  tuberculosis  vaccine,  Bacille 
Calmette­Guérin  (BCG),  protects  young  children  from 
the worse forms of the disease [65,66], but it is of limited 
use in adults [4]. Therefore, much M. tuberculosis vaccine 
research is focused on a prime­boost approach, a series 
of two vaccines, with BCG as the primary vaccine and a 
second experimental vaccine designed to re­activate and 
increase the protective memory response. As the boost 
several  substances  have  been  tried.  For  example,  a 
modified vaccinia virus (MVA) that expresses a protein 
from  M.  tuberculosis,  85A,  has  been  tested  in  animals 
and humans. By using a vaccinia vector, a broad immune 
response, including IL­12 production by DCs and IFNγ 
production by CD4 cells, is induced [67,68]. In mouse 
studies,  boosting  with  MVA85A  resulted  in  reduced 
levels  of  bacteria  in  challenged  animals  [69,70].  The 
vaccine also successfully boosts antigen­specific cells in 
humans  and  the  consequent  memory  cells  produce  a 
range of cytokines, including IFNγ and tumor necrosis 
factor (TNF)α [71­73]. Such multifunctional cells, which 
also make cytokines at higher levels, have been shown to 
provide  protection  against  infections,  including 
M. tuberculosis, in mouse models [55,73,74].
CD8 T cell-mediated protection
Although it has been difficult to demonstrate direct protec­
tive effects of CD4 memory T cells, the differen  tiation of 
CD8+ T cells into CTLs has long been a measure of their 
protective  efficacy  (Figure  1).  Following  activation  and 
clonal expansion in lymphoid organs, CTLs migrate to sites 
of inflammation, where they kill infected cells by inducing 
apoptosis,  thus  limiting  and  eventually  clearing  the 
infection. CTLs have been shown to provide protection in 
various mouse infection models [3,75­78], and CTL activity 
has  been  demonstrated  in  assays  in  vitro  using  human 
Figure 2. CD4+ T helper subsets. CD4+ T cells can differentiate into different subsets depending on the cytokine milieu present during T cell 
activation. TH1 cells, activated in the presence of IL-12 and IL-18 produced by activated DCs, make IFNγ, which is important in activating macrophages 
to kill intracellular bacteria, such as M. tuberculosis. IL-4 made by TH2 cells activates macrophages to expel parasites (the cellular source of the IL-4 that 
promotes TH2 development is currently poorly defined). T follicular (Tfh) cells can make the canonical cytokines that TH1 or TH2 cells produce, but 
they also make IL-21 and express cell-surface molecules, such as CD40 ligand and inducible T cell co-simulator (ICOS), that are required for effective B 
cell responses and production of high-affinity, class-switched antibodies. The more recently described TH17 cells can produce IL-17 and IL-22 and are 
generated in the presence of IL-6 and TGFβ. IL-17 and IL-22 are important for promoting the influx of neutrophils to inflamed sites and the production 
of antimicrobial peptides, respectively. TH17 cells are thought to be important in defense against extracellular bacteria and fungi. Activated T cells can 
also differentiate into regulatory T cells (Tregs) in the presence of TGFβ and/or retinoic acid (RA). These cells can inhibit and control immune responses 
to prevent excessive inflammation through cell-surface molecules (such as CTLA-4) or cytokines, such as IL-10.
IL-12, IL-18
IL-4
IL-6+TGFβ TGFβ/retinoic acid
Th1
IL-6, IL-21
IFNγ activates macrophages to
 kill intracellular bacteria
IL-4 activates macrophages to 
expel parasitic worms
IL-17 attracts neutrophils
IL-22 induces antimicrobial peptide 
production
Tfh cells make IL-21, IL-4 and express CD40L 
and ICOS that help B cells make high 
affinity class switched antibody  
Tregs inhibit immune responses via cell 
surface molecules of cytokines such as IL-10
Th2
Tfh
Th17
Treg
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Page 6 of 10CD8+  T  cells  [23,79,80].  CTLs  are  also  correlated  with 
protection in humans infected with influenza [79,81,82].
There has been a shift in the focus of influenza vaccine 
development towards generating memory CD8+ T cells 
that  may  be  able  to  provide  more  cross­reactive 
protection;  this  is  because,  as  mentioned  above,  the 
antigens that CD8+ T cells recognize are found in less 
variable portions of the virus [23­30]. Several approaches 
have been developed, and perhaps the most interesting 
are those that target the lung, generating memory cells in 
the correct location to provide the most rapid protection. 
For example, peptides recognized by CD8+ T cells have 
been  combined  with  a  lipid  moiety,  Pam­2­Cys,  that 
activates a TLR on DCs to successfully prime protective 
CD8+  T  cells  [83].  When  delivered  intranasally,  this 
vaccine generates CD8+ T cells that migrate to the lung 
to provide immediate protection.
The  use  of  peptide  fragments  rather  than  whole 
antigens is a limitation for the outbred human population 
because different fragments are recognized by the T cells 
of  different  individuals,  and  a  very  large  number  of 
different  fragments  would  need  to  be  identified  and 
included. As an alternative, whole detergent­inactivated 
influenza virus can be combined with ISCOMs, which 
can deliver enclosed antigen directly to DCs and activate 
a  range  of  innate  cells,  generating  a  TH1  and  CTL 
response [84]. ISCOMs containing inactivated influenza 
virus have been used to generate an intranasal vaccine 
that includes all the viral proteins and can induce cross­
reactive  protection  [85].  This  protection  required  both 
CTL and antibodies, indicating that the ISCOM vaccine 
induced an effective cell­mediated and humoral response.
The killing of infected cells by CTLs and TH1 cells is an 
effective way to clear an infection with an intracellular 
pathogen. However, in some cases, such as infection of 
the liver by the hepatitis B virus, IFNγ­producing CD8+ 
T cells offer more effective protection because the virus 
can be cleared without the death of a large number of 
host cells [86]. In a similar vein, IFNγ­producing CD8+ 
T  cells  are  associated  with  protection  in  individuals 
vaccinated with the RTS,S malaria vaccine. This vaccine 
contains a protein from the parasite fused to a surface 
protein  from  the  hepatitis  B  virus  [87].  Although  not 
enough  is  known  about  the  mechanisms  by  which 
immune  individuals  resist  infection,  it  is  believed  that 
both  humoral  and  cell­mediated  immunity  directed 
against multiple antigens expressed at different stages of 
the parasite’s lifecycle are required for protection during 
malarial infection [88]. The adjuvant system used in the 
most successful malarial vaccine is AS02, a preparation 
that  contains  both  a  saponin  component  and  the  TLR 
agonist MPL formulated in a particulate system. Notably, 
both saponin and MPL were required to induce a modest 
level  of  protection  in  immunized  individuals  [89].  In 
contrast, vaccines using the same antigen with aluminum 
hydroxide  and  MPL  (AS04)  or  in  an  oil­in­water 
emulsion  (AS03)  induced  high  levels  of  antibody  but 
failed  to  protect  against  infection.  A  greater 
understanding of the responses in protected individuals 
may  help  to  efficiently  identify  more  effective  antigen­
adjuvant  combinations.  For  example,  the  successful 
adjuvant,  AS02,  promotes  CD8  responses,  TH1 
differentiation and broad antibody responses [90]. This 
suggests that both antibody­ and cell­mediated immunity 
have  important  roles  in  defense  against  this  complex 
pathogen.
In pursuit of the ideal adjuvant
The immune system has a diverse range of mechanisms 
at its disposal to deal with infectious organisms (Figures 1 
and 2). Successful vaccines should aim to activate several 
of these, creating a redundant protective response that 
can cope with mutations and pathogen escape strategies. 
Although live attenuated viral and bacterial vaccines can 
activate  all  arms  of  the  immune  system  [67,91,92], 
adjuvants have so far not reached this goal. By combining 
adjuvants, such as aluminum salts with MPL, or using 
prime­boost  strategies  using  DNA  and  then  viral  or 
bacterial  vectors,  both  humoral  and  cell­mediated 
responses  can  be  activated,  and  some  successes,  as 
discussed  above,  have  been  reported.  Yellow  fever  and 
smallpox  (vaccinia)  viruses  are  highly  effective  live 
vaccines that promote B and T cell memory and promote 
lifelong protection [91,93]. Recent work from the groups 
of Rafi Ahmed and Bali Pulendran into why the yellow 
fever  and  vaccinia  vaccines  work  so  well  may  provide 
markers  of  both  innate  activation  and  early  adaptive 
responses, providing biomarkers to evaluate the success 
of new vaccine and adjuvant strategies [91,92].
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